Tata group to launch India’s first CRISPR COVID-19 test
Tata group on Saturday said it had received approval from the Drug Controller General of India (DCGI) for the commercial launch of the country’s first CRISPR COVID-19 test.
This test uses an indigenously developed CRISPR technology for the detection of the genomic sequence of SARS-CoV-2 virus that causes COVID-19 disease, Tata Sons said in a statement.
The Tata CRISPR test is the world’s first diagnostic test to deploy a specially adapted Cas9 protein to successfully detect the virus causing COVID-19, said the company.
The test achieves accuracy levels of traditional RT-PCR tests, with quicker turnaround time, less expensive equipment, and better ease of use, said the company.
Moreover, CRISPR is a futuristic technology that can also be configured for detection of multiple other pathogens in the future.
This marks a significant achievement for the Indian scientific community, moving from research and development to a high-accuracy, scalable and reliable test in less than 100 days, it added.